Product Images Topotecan Hydrochloride

This is a graph showing the effectiveness of topotecan hydrochloride for injection in combination with cisplatin compared to cisplatin monotherapy over a period of 35 months. The y-axis represents the number of participants in the study who were at risk, while the x-axis represents the number of months on the study. The graph shows that the combination of topotecan hydrochloride and cisplatin resulted in a higher number of participants remaining at risk for a longer period of time compared to cisplatin alone.*

This text appears to be a mixture of medical and product information related to a drug called "Topotecan Hydrochloride". The text mentions dosage instructions, precautions, and side effects of the drug. It also talks about how to handle and store the drug, including its sensitivity to light. The text advises to wash injection contacts thoroughly and flush mucous membranes with water. It also warns that the drug is cytotoxic and has batch coding.*

This is a description of Topotecan Hydrochloride for Injection, a medication for intravenous use. The drug is contained in a single dose vial and must be diluted. The medication is manufactured by Accord Healthcare in Durham, NC and by Intas Pharmaceuticals Limited in Anmedabag-382 210, India. The vial contains topotecan hydrochloride equivalent to 4mg of topotecan rebase, 48mg mannitol, and other substances. The medication should be stored at 20 to 25°C and protected from light. The safe handling of the medication is important and certain precautions should be taken. The recommended dosage for the medication should be followed as indicated in the prescribing information.*